Tonix Pharmaceuticals to Present TNX-801 Vaccine Platform at World Vaccine Congress Europe

BERKELEY HEIGHTS, N.J., Oct. 15, 2026 /CourierPR/ -- Tonix Pharmaceuticals, a fully integrated, commercial-stage biopharmaceutical company, will present its latest vaccine platform, TNX-801, at the World Vaccine Congress Europe 2026, held in Amsterdam, Netherlands, from October 19 to 21, 2026. The company will also host a working group session on vector-based vaccine platforms.

TNX-801 is a live, attenuated, minimally replicative investigational vaccine platform based on horsepox virus. It is designed to protect against mpox and other infectious diseases. The company plans to initiate a Phase 1 study of TNX-801 in 2027, pending FDA clearance of an Investigational New Drug (IND) application.

Tonix Pharmaceuticals is known for its flagship product, TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8mg), which was the first treatment for fibromyalgia in over 15 years. The company’s commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is also advancing a pipeline of infectious disease programs, including a Phase 2-ready monoclonal antibody, TNX-4800 (anti-OspA mAb), for Lyme disease prevention in the U.S. Additionally, TNX-801 is in development for the prevention of mpox and smallpox. Within immunology, TNX-1500 (anti-CD40L mAb) is a Phase 2-ready, third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Tonix Pharmaceuticals will present the safety and efficacy of TNX-801 at the World Vaccine Congress Europe on October 21, 2026, at 1:15 p.m. Central European Summer Time (CEST). The presentation will be led by Farooq Nasar, Ph.D., MPH, Director of Virology at Tonix Pharmaceuticals’ Research and Development Center.

CEST. The session will be led by Sina Bavari, Ph.D., Executive Vice President of Infectious Disease at Tonix Pharmaceuticals, Gabriella Worwa, DVM, Ph.D., Study Director at Tonix Pharmaceuticals, and Matilu Mwau, a Senior Principal Clinical Research Scientist and Professor of Infectious Diseases at the Kenya Medical Research Institute (KEMRI).

Tonix Pharmaceuticals Holding Corp. is focused on central nervous system (CNS) disorders, infectious diseases, and immunology conditions with high unmet medical needs. The company’s forward-looking statements are subject to various risks and uncertainties, as detailed in its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026.